nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

02.12.2022 | Invited Review

Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies

verfasst von: Jacopo Sapienza, Marco Spangaro, Gilles J. Guillemin, Stefano Comai, Marta Bosia

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper daily functioning causing disability and costs for society. Biological determinants underlying cognitive impairment are only partially understood and there are no convincing pharmacological targets able to improve cognitive outcome. Mounting evidence has shown the involvement of the kynurenine pathway in the pathophysiology of schizophrenia, also concerning cognitive symptoms. Therefore, the action of specific metabolites of kynurenine could affects cognition in schizophrenia. To evaluate the impact of the metabolites of kynurenine pathway on cognitive functions in schizophrenia spectrum disorders, with a focus on the modulating role of gender, to identify predictors of cognitive functioning and hypothetical pharmacological targets able to resize disability by improving cognition, thus functioning and quality of life. A systematic review was performed in PubMed/MEDLINE and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses. All studies measuring the direct impact of kynurenine metabolites on cognitive performances in living individuals with schizophrenia spectrum disorders were included in the review. Six studies were included. The activation of the kynurenine pathway resulted associated with greater cognitive deficits in patients with schizophrenia and both elevations and reduction of metabolites seemed able to affect cognitive outcome. No modulating role of sex emerged. This systematic review provides evidence that the activation of the kynurenine pathway affects cognition in patients with schizophrenia and highlights this pathway as a possible future target for developing novel drugs toward this still unmet clinical need. However, evidence is still limited and future studies are needed to further clarify the relationship between kynurenine pathway and cognition in schizophrenia.

Tandon R, Nasrallah HA, Keshavan MS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 110:1–23. https://doi.org/10.1016/j.schres.2009.03.005CrossRefPubMed

Bechi M, Bosia M, Spangaro M et al (2017) Exploring functioning in schizophrenia: predictors of functional capacity and real-world behaviour. Psychiatry Res 251:118–124. https://doi.org/10.1016/J.PSYCHRES.2017.02.019CrossRefPubMed

Gebreegziabhere Y, Habatmu K, Mihretu A et al (2022) Cognitive impairment in people with schizophrenia: an umbrella review. Eur Arch Psychiatry Clin Neurosci 272:1139–1155. https://doi.org/10.1007/s00406-022-01416-6CrossRefPubMedPubMedCentral

Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36:211–218. https://doi.org/10.1093/SCHBUL/SBQ002CrossRefPubMedPubMedCentral

Krogmann A, Peters L, Von Hardenberg L et al (2019) Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr 24:41–68. https://doi.org/10.1017/S109285291900124XCrossRef

Bosia M, Spangaro M, Sapienza J et al (2021) Cognition in schizophrenia: modeling the interplay between interleukin-1β C-511T polymorphism, metabolic syndrome, and sex. Neuropsychobiology 80:321–332. https://doi.org/10.1159/000512082CrossRefPubMed

Zhang B, Han M, Tan S et al (2017) Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. Sci Rep 7:11821. https://doi.org/10.1038/S41598-017-12027-WCrossRefPubMedPubMedCentral

D. Howes O, Fusar-Poli P, Bloomfield M, et al (2012) From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des 18:459–465. https://doi.org/10.2174/138161212799316217CrossRef

Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35:549–562. https://doi.org/10.1093/schbul/sbp006CrossRefPubMedPubMedCentral

10.

Braver TS, Barch DM, Cohen JD (1999) Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry 46:312–328. https://doi.org/10.1016/S0006-3223(99)00116-XCrossRefPubMed

11.

Bosia M, Bechi M, Pirovano A et al (2014) COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Heal Psychol Behav Med 2:509–516. https://doi.org/10.1080/21642850.2014.905206CrossRef

12.

Bosia M, Pigoni A, Pirovano A et al (2015) COMT and STH polymorphisms interaction on cognition in schizophrenia. Neurol Sci 36:215–220. https://doi.org/10.1007/S10072-014-1936-9CrossRefPubMed

13.

Bosia M, Bechi M, Marino E et al (2007) Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett 417:271–274. https://doi.org/10.1016/j.neulet.2007.02.076CrossRefPubMed

14.

He Q, Xue G, Chen C et al (2012) COMT Val158Met polymorphism interacts with stressful life events and parental warmth to influence decision making. Sci Rep 2:677. https://doi.org/10.1038/SREP00677CrossRefPubMedPubMedCentral

15.

Koola MM (2021) Alpha7 nicotinic-N-methyl-d-aspartate hypothesis in the treatment of schizophrenia and beyond. Hum Psychopharmacol 36:1–16. https://doi.org/10.1002/HUP.2758CrossRefPubMed

16.

Spangaro M, Bosia M, Zanoletti A et al (2012) Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci Lett 522:151–155. https://doi.org/10.1016/J.NEULET.2012.06.030CrossRefPubMed

17.

Spangaro M, Bosia M, Zanoletti A et al (2014) Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics 15:925–932. https://doi.org/10.2217/PGS.14.42CrossRefPubMed

18.

Khandaker GM, Cousins L, Deakin J et al (2015) Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2:258–270. https://doi.org/10.1016/S2215-0366(14)00122-9CrossRefPubMedPubMedCentral

19.

Kogan S, Ospina LH, Mittal VA, Kimhy D (2019) The impact of inflammation on neurocognition and risk for psychosis: a critical review. Eur Arch Psychiatry Clin Neurosci 270:793–802. https://doi.org/10.1007/s00406-019-01073-2CrossRefPubMedPubMedCentral

20.

Yamada S, Takahashi S, Malchow B et al (2022) Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 272:957–969. https://doi.org/10.1007/s00406-021-01363-8CrossRefPubMed

21.

Na KS, Jung HY, Kim YK (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 48:277–286. https://doi.org/10.1016/j.pnpbp.2012.10.022CrossRef

22.

Maas DA, Vallès A, Martens GJM (2017) Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry 7:e1171. https://doi.org/10.1038/TP.2017.138CrossRefPubMedPubMedCentral

23.

Smirnova LP, Yarnykh VL, Parshukova DA et al (2021) Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction. Transl Psychiatry 11:365. https://doi.org/10.1038/s41398-021-01475-8CrossRefPubMedPubMedCentral

24.

Noto MN, Maes M, Nunes SOV et al (2019) Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. Eur Neuropsychopharmacol 29:416–431. https://doi.org/10.1016/j.euroneuro.2018.12.008CrossRefPubMed

25.

Comai S, Bertazzo A, Brughera M, Crotti S (2020) Tryptophan in health and disease. Adv Clin Chem 95:165–218. https://doi.org/10.1016/BS.ACC.2019.08.005CrossRefPubMed

26.

Comai S, Melloni E, Lorenzi C et al (2022) Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression. Eur Neuropsychopharmacol 55:96–109. https://doi.org/10.1016/J.EURONEURO.2021.11.003CrossRefPubMed

27.

Pires AS, Sundaram G, Heng B et al (2021) Recent advances in clinical trials targeting the kynurenine pathway. Pharmacol Ther 236:108055. https://doi.org/10.1016/J.PHARMTHERA.2021.108055CrossRefPubMed

28.

Kindler J, Lim CK, Weickert CS et al (2020) Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry 25:2860–2872. https://doi.org/10.1038/S41380-019-0401-9CrossRefPubMed

29.

de Bie J, Lim CK, Guillemin GJ (2016) Kynurenines, gender and neuroinflammation; showcase schizophrenia. Neurotox Res 30:285–294. https://doi.org/10.1007/S12640-016-9641-5CrossRefPubMed

30.

Schwarcz R, Stone TW (2017) The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology 112:237–247. https://doi.org/10.1016/J.NEUROPHARM.2016.08.003CrossRefPubMed

31.

Comai S, Bertazzo A, Carretti N et al (2010) Serum levels of tryptophan, 5-hydroxytryptophan and serotonin in patients affected with different forms of amenorrhea. Int J Tryptophan Res 3:69–75. https://doi.org/10.4137/IJTR.S3804CrossRefPubMedPubMedCentral

32.

Carretti N, Florio P, Bertolin A et al (2005) Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization. Hum Reprod 20:1548–1553. https://doi.org/10.1093/HUMREP/DEH795CrossRefPubMed

33.

Carretti N, Florio P, Reis FM et al (2007) Menopause alters the metabolism of serum serotonin precursors and their correlation with gonadotropins and estradiol. Climacteric 10:393–399. https://doi.org/10.1080/13697130701378198CrossRefPubMed

34.

De Bie J, Guest J, Guillemin GJ, Grant R (2016) Central kynurenine pathway shift with age in women. J Neurochem 136:995–1003. https://doi.org/10.1111/JNC.13496CrossRefPubMed

35.

Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477. https://doi.org/10.1038/NRN3257CrossRefPubMedPubMedCentral

36.

Roomruangwong C, Noto C, Kanchanatawan B et al (2020) The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia. Mol Neurobiol 57:778–797. https://doi.org/10.1007/S12035-019-01737-ZCrossRefPubMed

37.

Comai S, Costa CVL, Ragazzi E et al (2005) The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. Clin Chim Acta 360:67–80. https://doi.org/10.1016/J.CCCN.2005.04.013CrossRefPubMed

38.

Fujigaki H, Mouri A, Yamamoto Y et al (2019) Linking phencyclidine intoxication to the tryptophan–kynurenine pathway: therapeutic implications for schizophrenia. Neurochem Int 125:1–6. https://doi.org/10.1016/j.neuint.2019.02.001CrossRefPubMed

39.

Hilmas C, Pereira EFR, Alkondon M et al (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473. https://doi.org/10.1523/JNEUROSCI.21-19-07463.2001CrossRefPubMedPubMedCentral

40.

Gibbons A, Dean B (2016) The cholinergic system: an emerging drug target for schizophrenia. Curr Pharm Des 22:2124–2133. https://doi.org/10.2174/1381612822666160127114010CrossRefPubMed

41.

Bai MY, Lovejoy DB, Guillemin GJ et al (2021) Galantamine–memantine combination and kynurenine pathway enzyme inhibitors in the treatment of neuropsychiatric disorders. Complex psychiatry 7:19–33. https://doi.org/10.1159/000515066CrossRefPubMedPubMedCentral

42.

Anderson G, Maes M (2013) Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuro-Psychopharmacol Biol Psychiatry 42:5–19. https://doi.org/10.1016/j.pnpbp.2012.06.014CrossRef

43.

Upthegrove R, Khandaker GM (2020) Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr Top Behav Neurosci 44:49–66. https://doi.org/10.1007/7854_2018_88CrossRefPubMed

44.

Flatow J, Buckley P, Miller BJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 74:400–409. https://doi.org/10.1016/j.biopsych.2013.03.018CrossRefPubMedPubMedCentral

45.

Howes OD, McCutcheon R (2017) Inflammation and the neural diathesis–stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry 7:e1024–e1111. https://doi.org/10.1038/tp.2016.278CrossRefPubMedPubMedCentral

46.

Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671. https://doi.org/10.1016/j.biopsych.2011.04.013CrossRefPubMedPubMedCentral

47.

Momtazmanesh S, Zare-Shahabadi A, Rezaei N (2019) Cytokine alterations in schizophrenia: an updated review. Front Psychiatry 10:892. https://doi.org/10.3389/FPSYT.2019.00892CrossRefPubMedPubMedCentral

48.

Chiappelli J, Notarangelo FM, Pocivavsek A et al (2018) Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. Neuropsychopharmacology 43:1675–1680. https://doi.org/10.1038/S41386-018-0038-4CrossRefPubMedPubMedCentral

49.

Savitz J (2020) The kynurenine pathway: a finger in every pie. Mol Psychiatry 25:131–147. https://doi.org/10.1038/S41380-019-0414-4CrossRefPubMed

50.

Pocivavsek A, Thomas MAR, Elmer GI et al (2014) Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology 231:2799–2809. https://doi.org/10.1007/S00213-014-3452-2CrossRefPubMedPubMedCentral

51.

Pershing ML, Bortz DM, Pocivavsek A et al (2015) Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology 90:33–41. https://doi.org/10.1016/J.NEUROPHARM.2014.10.017CrossRefPubMed

52.

Erhardt S, Pocivavsek A, Repici M et al (2017) Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders. Biol Psychiatry 82:756–765. https://doi.org/10.1016/J.BIOPSYCH.2016.12.011CrossRefPubMed

53.

Almulla AF, Vasupanrajit A, Tunvirachaisakul C et al (2022) The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry. https://doi.org/10.1038/S41380-022-01552-4CrossRefPubMedPubMedCentral

54.

Kanchanatawan B, Hemrungrojn S, Thika S et al (2018) Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia. Mol Neurobiol 55:5184–5201. https://doi.org/10.1007/S12035-017-0751-8CrossRefPubMed

55.

Kirkpatrick B, Buchanan RW, McKenny PD et al (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123. https://doi.org/10.1016/0165-1781(89)90153-4CrossRefPubMed

56.

Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry 7:143–147. https://doi.org/10.1002/J.2051-5545.2008.TB00181.XCrossRefPubMedPubMedCentral

57.

Bechi M, Spangaro M, Agostoni G et al (2019) Intellectual and cognitive profiles in patients affected by schizophrenia. J Neuropsychol 13:589–602. https://doi.org/10.1111/JNP.12161CrossRefPubMed

58.

Huang X, Ding W, Wu F et al (2020) Increased plasma kynurenic acid levels are associated with impaired attention/vigilance and social cognition in patients with schizophrenia. Neuropsychiatr Dis Treat 16:263–271. https://doi.org/10.2147/NDT.S239763CrossRefPubMedPubMedCentral

59.

Huang J, Tong J, Zhang P et al (2021) Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia. Transl Psychiatry 11:198. https://doi.org/10.1038/S41398-021-01311-ZCrossRefPubMedPubMedCentral

60.

Cathomas F, Guetter K, Seifritz E et al (2021) Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. Sci Rep 11:9992. https://doi.org/10.1038/S41598-021-89335-9CrossRefPubMedPubMedCentral

61.

Noyan H, Erdağ E, Tüzün E et al (2021) Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophr Res 229:27–37. https://doi.org/10.1016/J.SCHRES.2021.01.014CrossRefPubMed

62.

Badawy AAB, Guillemin G (2019) The plasma [kynurenine]/[tryptophan] ratio and indoleamine 2,3-dioxygenase: time for appraisal. Int J Tryptophan Res 12:1178646919868978. https://doi.org/10.1177/1178646919868978CrossRefPubMedPubMedCentral

63.

Fukui S, Schwarcz R, Rapoport SI et al (1991) Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017. https://doi.org/10.1111/J.1471-4159.1991.TB03460.XCrossRefPubMed

64.

Pollak TA, Drndarski S, Stone JM et al (2018) The blood–brain barrier in psychosis. Lancet Psychiatry 5:79–92. https://doi.org/10.1016/S2215-0366(17)30293-6CrossRefPubMed

65.

Fellendorf FT, Manchia M, Squassina A et al (2022) Is poor lithium response in individuals with bipolar disorder associated with increased degradation of tryptophan along the kynurenine pathway? Results of an exploratory study. J Clin Med 11:2517. https://doi.org/10.3390/JCM11092517CrossRefPubMedPubMedCentral

66.

Braidy N, Grant R, Brew BJ et al (2009) Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons. Int J Tryptophan Res 2:61–69. https://doi.org/10.4137/IJTR.S2318CrossRefPubMedPubMedCentral

67.

Braidy N, Guillemin GJ, Grant R (2011) Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res 4:29–37. https://doi.org/10.4137/IJTR.S7052CrossRefPubMedPubMedCentral

68.

Plitman E, Nakajima S, de la Fuente-Sandoval C et al (2014) Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol 24:1591–1605. https://doi.org/10.1016/J.EURONEURO.2014.07.015CrossRefPubMedPubMedCentral

69.

Shah P, Plitman E, Iwata Y et al (2020) Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: implications for glutamate-mediated excitotoxicity. J Psychiatr Res 124:151–158. https://doi.org/10.1016/J.JPSYCHIRES.2020.02.032CrossRefPubMed

70.

Zhang Y, Catts VS, Sheedy D et al (2016) Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. Transl Psychiatry 6:e982. https://doi.org/10.1038/TP.2016.238CrossRefPubMedPubMedCentral

71.

Wu D, Lv P, Li F et al (2019) Association of peripheral cytokine levels with cerebral structural abnormalities in schizophrenia. Brain Res 1724:146463. https://doi.org/10.1016/J.BRAINRES.2019.146463CrossRefPubMed

72.

Leung A, Chue P (2000) Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 401:3–38. https://doi.org/10.1111/J.0065-1591.2000.0AP25.XCrossRefPubMed

73.

Al-Hakeim HK, Almulla AF, Maes M (2020) The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizophrenia: a supervised machine learning study. Neurotox Res 37:753–771. https://doi.org/10.1007/s12640-019-00112-zCrossRefPubMed

74.

Al-Hakeim HK, Almulla AF, Al-Dujaili AH, Maes M (2020) Construction of a neuro-immune-cognitive pathway-phenotype underpinning the phenome of deficit schizophrenia. Curr Top Med Chem 20:747–758. https://doi.org/10.2174/1568026620666200128143948CrossRefPubMed

75.

Maes M, Vojdani A, Sirivichayakul S et al (2021) Inflammatory and oxidative pathways are new drug targets in multiple episode schizophrenia and leaky gut, Klebsiella pneumoniae, and C1q immune complexes are additional drug targets in first episode schizophrenia. Mol Neurobiol 58:3319–3334. https://doi.org/10.1007/s12035-021-02343-8CrossRefPubMed

76.

Al-Hakeim HK, Mousa RF, Al-Dujaili AH, Maes M (2021) In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy. Metab Brain Dis 36:939–955. https://doi.org/10.1007/S11011-021-00685-9CrossRefPubMed

77.

Maes M, Kanchanatawan B (2021) In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. CNS Spectr 12:1–10. https://doi.org/10.1017/S1092852921000419CrossRef

78.

Lim K, Smucny J, Barch DM et al (2021) Cognitive subtyping in schizophrenia: a latent profile analysis. Schizophr Bull 47:712–721. https://doi.org/10.1093/schbul/sbaa157CrossRefPubMed

79.

North HF, Bruggemann J, Cropley V et al (2021) Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. Eur Arch Psychiatry Clin Neurosci 271:595–607. https://doi.org/10.1007/S00406-021-01237-ZCrossRefPubMed

80.

de Bie J, Lim CK, Guillemin GJ (2016) Progesterone alters kynurenine pathway activation in IFN-γ-activated macrophages—relevance for neuroinflammatory diseases. Int J Tryptophan Res 9:89–93. https://doi.org/10.4137/IJTR.S40332CrossRefPubMedPubMedCentral

Titel: Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies
verfasst von: Jacopo Sapienza
Marco Spangaro
Gilles J. Guillemin
Stefano Comai
Marta Bosia
Publikationsdatum: 02.12.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2023
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-022-01519-0

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies

Abstract

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2023

Neuropsychiatric post-acute sequelae of COVID-19: prevalence, severity, and impact of vaccination

Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance

Phenotypic and genetic factors associated with donation of DNA and consent to record linkage for prescription history in the Australian Genetics of Depression Study

Reduced cortical neuron number and neuron density in schizophrenia with focus on area 24: a post-mortem case–control study

Facial and upper-limb movement abnormalities in individuals with psychotic-like experiences: a motion analysis study

Reduced anterior insular cortex volume in male heroin addicts: a postmortem study

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie